WO2026104883 - MONOCLONAL MOUSE ANTIBODIES AGAINST HUMAN ESTROGEN RECEPTOR, HUMAN PROGESTERONE RECEPTOR, HUMAN KI-67, AND HUMAN P53
National phase entry is expected:
Publication Number
WO/2026/104883
Publication Date
21.05.2026
International Application No.
PCT/IB2024/061474
International Filing Date
17.11.2024
Title **
[English]
MONOCLONAL MOUSE ANTIBODIES AGAINST HUMAN ESTROGEN RECEPTOR, HUMAN PROGESTERONE RECEPTOR, HUMAN KI-67, AND HUMAN P53
[French]
ANTICORPS MONOCLONAUX DE SOURIS DIRIGÉS CONTRE LE RÉCEPTEUR DES ŒSTROGÈNES HUMAINS, LE RÉCEPTEUR DE LA PROGESTÉRONE HUMAINE, KI-67 HUMAIN, ET P53 HUMAIN
Applicants **
FARZAM, Mohammad
Inventors
FARZAM, Mohammad
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
IP India
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Natural Person
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1885 | |
| EPO | Filing, Examination, Granting | 8703 | |
| Japan | Filing, Examination, Granting | 1820 | |
| South Korea | Filing, Examination, Granting | 1307 | |
| USA | Filing, Examination, Granting | 5340 |
Total:
19,055
Contact Us
Abstract[English]
Breast cancer is a serious type of cancer that affects many women each year, often leading to death. To choose the right treatment for breast cancer, studying biomarkers is crucial, and one way to do this is by using the immunohistochemical technique (IHC). Biomarkers like Estrogen receptor (ER), progesterone receptor (PR), Ki67, and P53 play a crucial role in determining the prognosis, progression, and response to treatment of breast cancer. Specific monoclonal antibodies against these biomarkers were created by immunizing mice with peptides derived from these proteins. These antibodies were then tested for specificity using ELISA and IHC staining on normal and cancerous tissues, confirming their ability to recognize the receptors. Additionally, the antibodies were evaluated for isotype, affinity constant, and their ability to detect natural antigens in flow cytometry and western blot.[French]
Le cancer du sein est un type de cancer grave qui affecte de nombreuses femmes chaque année, conduisant souvent à la mort. Pour choisir le bon traitement contre le cancer du sein, l'étude des biomarqueurs est cruciale, et l'une des manières d'y parvenir est d'utiliser la technique immunohistochimique (IHC). Des biomarqueurs tels que le récepteur des œstrogènes (ER), le récepteur de la progestérone (PR), Ki67 et P53 jouent un rôle crucial dans la détermination du pronostic, de la progression et de la réponse au traitement du cancer du sein. Des anticorps monoclonaux spécifiques dirigés contre ces biomarqueurs ont été créés par immunisation de souris avec des peptides dérivés de ces protéines. Ces anticorps ont ensuite été testés pour une spécificité utilisant une coloration ELISA et IHC sur des tissus normaux et cancéreux, confirmant leur capacité à reconnaître les récepteurs. De plus, les anticorps ont été évalués pour l'isotype, la constante d'affinité et leur capacité à détecter des antigènes naturels dans la cytométrie en flux et le transfert Western.